3 days popular7 days popular1 month popular3 months popular

Rooting Out Recurrent Breast Cancer

Due to chemotherapy resistance and a high rate of relapse, triple negative cancers are among the most difficult to treat.

In this issue of the Journal of Clinical Investigation, researchers led by at Vanderbilt University identified a protein, -β, that is highly expressed in triple negative breast cells after chemotherapy.

In a mouse model of , TGF-β both diverted cells down a path to becoming cancerous and allowed for cancer to come back after treatment. Importantly, loss of TGF-β prevented tumor recurrence in mice. These studies identify a mechanism by which cancer cells elude standard chemotherapy and provide a rationale for testing the therapeutic potential of agents that block TGF-β.

TITLE: TGFβ inhibition enhances chemotherapy action against triple negative breast cancer



Journal of Clinical Investigation